No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shanghai Shyndec Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of pharmaceutical products. The company focuses on five major therapeutic areas: anti-infection, cardiovascular, anti-tumor and immunomodulation, metabolic and endocrine, and anesthesia and psychotropics. It is principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and drug preparations, distributing its products in domestic and overseas markets.
www.shyndec.comNo one on the platform currently holds 600420.SS.
No tracked institution reports a position in 600420.SS as of their last filing.
No one on the platform has traded 600420.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.0% | 11.6% | 11.3% | — | — | — |
| Rev. Growth % | -14.4% | -5.7% | ||||
| Profit Margin % | 10.1% | 6.9% | 6.3% | |||
| Free Cash Flow Margin % | 15.3% | 14.6% | 13.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.0B | -20.1% | $0.63 | $0.63–$0.63 | — | 1 |
| 2027 | $9.1B | +1.6% | $0.69 | $0.69–$0.69 | — | 1 |
| 2028 | $9.5B | +3.8% | $0.76 | $0.76–$0.76 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600420.SSShanghai Shyndec Pharmaceutical Co., Ltd. | $8.20 | -0.61% | $11.0B | — |
| 000403.SZPacific Shuanglin Bio-pharmacy Co., Ltd. | $9.94 | -0.60% | $9.4B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.37 | -0.79% | $9.8B | — |
| 600211.SSTibet Rhodiola Pharmaceutical Holding Co. Class A | $35.73 | -1.05% | $11.5B | — |
| 600216.SSZhejiang Medicine Co., Ltd. |
| $12.37 |
| -0.96% |
| $11.9B |
| — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. | $11.37 | +0.62% | $13.4B | — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.07 | -1.04% | $10.8B | — |
Source: Financial Modeling Prep · peers by sector/industry